This report analyzes the disruptive themes that have driven M&A activity in Q3 2022 in the Pharma Sector
The pharma sector recorded a 13% decrease in M&A deal value and also saw decrease of 9% in deal volume compared to the previous quarter. There were eight M&A deals in Q3 2022 with a deal size greater than $1 billion, compared to four such deals in the previous quarter.
Scope
- This report provides an overview of merger and acquisition activity globally in Q3 2022 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q3 2022 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.